{"transactions":[{"id":4616750,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:09.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":2081,"price":33.0919,"value":68864.2439,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.85 to $33.29. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":278064,"source":{"system":"sec-edgar","filing":"0001193125-26-390510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390510/ownership.xml","form_type":"4"}},{"id":4616749,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:09.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":7947,"price":32.2139,"value":256003.8633,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.76 to $32.68. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":280145,"source":{"system":"sec-edgar","filing":"0001193125-26-390510","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390510/ownership.xml","form_type":"4"}},{"id":671084,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9730,"price":49.13,"value":478034.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671083,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10350,"price":52.67,"value":545134.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671082,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":40.29,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671081,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.68,"value":1131900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671080,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":66.71,"value":1167425.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671079,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.77,"value":1133475.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-22","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671078,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"price":68.92,"value":1723000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":16.08,"expiration_date":"2030-09-01","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671077,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5925,"price":85,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":671076,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:00:18.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16300,"price":85,"value":1385500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":5925,"source":{"system":"sec-edgar","filing":"0001628280-26-059900","document":"wk-form4_1788296414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059900/wk-form4_1788296414.xml","form_type":"4"}},{"id":679859,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:05.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":22807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":288092,"source":{"system":"sec-edgar","filing":"0001193125-26-359676","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359676/ownership.xml","form_type":"4"}},{"id":730461,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:02:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":9730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9730,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-044712","document":"wk-form4_1782162151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044712/wk-form4_1782162151.xml","form_type":"4"}},{"id":730460,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T21:02:33.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the\nfirst anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through\nsuch vesting date."}],"balance_after":22225,"source":{"system":"sec-edgar","filing":"0001628280-26-044712","document":"wk-form4_1782162151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044712/wk-form4_1782162151.xml","form_type":"4"}},{"id":853494,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-09T20:00:03.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":143985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer\nthrough each such vesting date."}],"balance_after":143985,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":143985},"source":{"system":"sec-edgar","filing":"0001193125-26-098436","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098436/ownership.xml","form_type":"4"}},{"id":853493,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:03.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":95990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting\nPerson's continued service to the Issuer through each such vesting date."}],"balance_after":265285,"source":{"system":"sec-edgar","filing":"0001193125-26-098436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098436/ownership.xml","form_type":"4"}},{"id":861574,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:07.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":6461,"price":14.5806,"value":94205.2566,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.440 to $14.945. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":169295,"source":{"system":"sec-edgar","filing":"0001193125-26-091440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526091440/ownership.xml","form_type":"4"}},{"id":981512,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-12-03T21:39:50.000Z","date":"2025-12-01","kind":"sale","planned":false,"acquired":false,"shares":6580,"price":14.3493,"value":94418.394,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.30 to $14.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":175756,"source":{"system":"sec-edgar","filing":"0001193125-25-306818","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525306818/ownership.xml","form_type":"4"}},{"id":1027180,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:08.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":12039,"price":14.5791,"value":175517.7849,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.04. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":182336,"source":{"system":"sec-edgar","filing":"0001193125-25-228339","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525228339/ownership.xml","form_type":"4"}},{"id":1100908,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-26T20:56:04.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":4712,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4712,"derivative":{"underlying":"Common Stock","underlying_shares":4712},"source":{"system":"sec-edgar","filing":"0001104659-25-063080","document":"tm2519230-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465925063080/tm2519230-3_4seq1.xml","form_type":"4"}},{"id":1100907,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-26T20:56:04.000Z","date":"2025-06-24","kind":"grant","planned":false,"acquired":true,"shares":7037,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 24, 2026 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2026, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":7037,"derivative":{"exercise_price":63.66,"expiration_date":"2035-06-23","underlying":"Common Stock","underlying_shares":7037},"source":{"system":"sec-edgar","filing":"0001104659-25-063080","document":"tm2519230-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465925063080/tm2519230-3_4seq1.xml","form_type":"4"}},{"id":1103543,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2025-06-23T20:52:05.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-25-061711","document":"tm2518591-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465925061711/tm2518591-4_4seq1.xml","form_type":"4"}},{"id":1103542,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-23T20:52:05.000Z","date":"2025-06-18","kind":"exercise","planned":false,"acquired":true,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":7000,"source":{"system":"sec-edgar","filing":"0001104659-25-061711","document":"tm2518591-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465925061711/tm2518591-4_4seq1.xml","form_type":"4"}},{"id":1111618,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":10350,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0000950170-25-086265","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086265/ownership.xml","form_type":"4"}},{"id":1111617,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:15.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":16300,"source":{"system":"sec-edgar","filing":"0000950170-25-086265","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086265/ownership.xml","form_type":"4"}},{"id":1183408,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-04-02T21:14:24.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":12425,"price":3.4674,"value":43082.445,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":194375,"source":{"system":"sec-edgar","filing":"0000950170-25-049567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025049567/ownership.xml","form_type":"4"}},{"id":1215018,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:32:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":102630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":102630,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":102630},"source":{"system":"sec-edgar","filing":"0000950170-25-036712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036712/ownership.xml","form_type":"4"}},{"id":1215017,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:32:03.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":68420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":206800,"source":{"system":"sec-edgar","filing":"0000950170-25-036712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036712/ownership.xml","form_type":"4"}},{"id":1344994,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-12-03T22:21:26.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":5421,"price":5.5354,"value":30007.4034,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.475 to $5.59. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":138380,"source":{"system":"sec-edgar","filing":"0000950170-24-132885","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024132885/ownership.xml","form_type":"4"}},{"id":1394416,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-10-02T22:50:13.000Z","date":"2024-09-30","kind":"sale","planned":false,"acquired":false,"shares":11442,"price":3.1952,"value":36559.4784,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.125 to $3.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":143801,"source":{"system":"sec-edgar","filing":"0000950170-24-111809","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024111809/ownership.xml","form_type":"4"}},{"id":1469374,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-25T20:37:07.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units fully vested on June 21, 2024. The restricted stock units have no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-24-074767","document":"tm2418139-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465924074767/tm2418139-3_4seq1.xml","form_type":"4"}},{"id":1469373,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-25T20:37:07.000Z","date":"2024-06-21","kind":"exercise","planned":false,"acquired":true,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001104659-24-074767","document":"tm2418139-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465924074767/tm2418139-3_4seq1.xml","form_type":"4"}},{"id":1472910,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2024-06-21T01:41:10.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":4000,"derivative":{"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001104659-24-073634","document":"tm2417588-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465924073634/tm2417588-3_4seq1.xml","form_type":"4"}},{"id":1472909,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-21T01:41:10.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 18, 2025 or (ii) the date of the Issuer's annual meeting of the stockholders to be held in 2025, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":41.39,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-24-073634","document":"tm2417588-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465924073634/tm2417588-3_4seq1.xml","form_type":"4"}},{"id":1483427,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-11T20:19:10.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-071923","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071923/ownership.xml","form_type":"4"}},{"id":1483426,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:19:10.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9400,"source":{"system":"sec-edgar","filing":"0000950170-24-071923","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071923/ownership.xml","form_type":"4"}},{"id":1539207,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-19T00:19:34.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-24-045693","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024045693/ownership.xml","form_type":"4"}},{"id":1539206,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:19:34.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":96910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":155243,"source":{"system":"sec-edgar","filing":"0000950170-24-045693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024045693/ownership.xml","form_type":"4"}},{"id":1727653,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-11-29T21:49:00.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option shall vest and become exercisable on December 1, 2024, with the remainder vesting in a series of 36 successive monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":162500,"derivative":{"exercise_price":12.93,"expiration_date":"2033-11-26","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0000950170-23-066796","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023066796/ownership.xml","form_type":"4"}},{"id":1727652,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-11-29T21:49:00.000Z","date":"2023-11-27","kind":"grant","planned":false,"acquired":true,"shares":58333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSU shall vest in 4 annual installments, with the first installment vesting on December 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date."}],"balance_after":58333,"source":{"system":"sec-edgar","filing":"0000950170-23-066796","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023066796/ownership.xml","form_type":"4"}},{"id":1844991,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2023-06-23T20:30:59.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001104659-23-074292","document":"tm2319485-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465923074292/tm2319485-2_4seq1.xml","form_type":"4"}},{"id":1844990,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:30:59.000Z","date":"2023-06-21","kind":"grant","planned":false,"acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 21, 2024 or (ii) the date of the Issuer's next annual meeting of the stockholders, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":14000,"derivative":{"exercise_price":18.47,"expiration_date":"2033-06-20","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001104659-23-074292","document":"tm2319485-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465923074292/tm2319485-2_4seq1.xml","form_type":"4"}},{"id":1847813,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:13.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-038818","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038818/doc4.xml","form_type":"4"}},{"id":1847812,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T21:00:13.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001209191-23-038818","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038818/doc4.xml","form_type":"4"}},{"id":1972354,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:00:36.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":3881,"price":45.25,"value":175615.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":46720,"source":{"system":"sec-edgar","filing":"0001209191-23-016053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919123016053/doc4.xml","form_type":"4"}},{"id":1972353,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-03-04T01:00:36.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":2663,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock into which previously granted performance stock units were converted on March 1, 2023 upon certification of the performance metric."}],"balance_after":50601,"source":{"system":"sec-edgar","filing":"0001209191-23-016053","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919123016053/doc4.xml","form_type":"4"}},{"id":2225432,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T20:44:45.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-038435","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122038435/doc4.xml","form_type":"4"}},{"id":2235608,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:09:05.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 8, 2023 or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":20000,"derivative":{"exercise_price":4.15,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-22-070117","document":"tm2218129-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465922070117/tm2218129-2_4seq1.xml","form_type":"4"}},{"id":2353384,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-03T23:07:00.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":24900,"derivative":{"exercise_price":67.37,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-22-015802","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919122015802/doc4.xml","form_type":"4"}},{"id":2353383,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:07:00.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Award of RSUs under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":47938,"source":{"system":"sec-edgar","filing":"0001209191-22-015802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919122015802/doc4.xml","form_type":"4"}},{"id":2353382,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-03-03T23:07:00.000Z","date":"2022-03-01","kind":"sale","acquired":false,"shares":2821,"price":66.62,"value":187935.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."}],"balance_after":33938,"source":{"system":"sec-edgar","filing":"0001209191-22-015802","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919122015802/doc4.xml","form_type":"4"}},{"id":2418928,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-02-01T18:39:50.000Z","date":"2022-01-30","kind":"sale","acquired":false,"shares":1657,"price":66.3,"value":109859.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":36759,"source":{"system":"sec-edgar","filing":"0001209191-22-005838","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919122005838/doc4.xml","form_type":"4"}},{"id":2540392,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-10-18T23:02:01.000Z","date":"2021-10-14","kind":"sale","acquired":false,"shares":359,"price":81.14,"value":29129.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":38416,"source":{"system":"sec-edgar","filing":"0001209191-21-060765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121060765/doc4.xml","form_type":"4"}},{"id":2581242,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-02","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the \"Option Anniversary Date\") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date."}],"balance_after":53000,"derivative":{"exercise_price":55,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2581241,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-01","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the \"Option Anniversary Date\") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date."}],"balance_after":55500,"derivative":{"exercise_price":55,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2581240,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-02","kind":"sale","acquired":false,"shares":2500,"price":100.18,"value":250450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":38775,"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2581239,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-02","kind":"exercise","acquired":true,"shares":2500,"price":55,"value":137500.0,"ownership":{"direct":true},"balance_after":41275,"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2581238,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-01","kind":"sale","acquired":false,"shares":2500,"price":100.03,"value":250075.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":38775,"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2581237,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-09-02T22:11:04.000Z","date":"2021-09-01","kind":"exercise","acquired":true,"shares":2500,"price":55,"value":137500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":41275,"source":{"system":"sec-edgar","filing":"0001209191-21-054542","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121054542/doc4.xml","form_type":"4"}},{"id":2657096,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-23T21:00:21.000Z","date":"2021-06-22","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-21-042766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121042766/doc4.xml","form_type":"4"}},{"id":2671512,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T20:05:50.000Z","date":"2021-06-09","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options fully vest upon the earlier of (i) June 9, 2022 or (ii) the date of the Issuer's next annual meeting of the stockholders."}],"balance_after":15000,"derivative":{"exercise_price":18.99,"expiration_date":"2031-06-08","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001104659-21-080099","document":"tm2119501-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465921080099/tm2119501-2_4seq1.xml","form_type":"4"}},{"id":2720607,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-05-10T22:09:49.000Z","date":"2021-05-06","kind":"sale","acquired":false,"shares":364,"price":113.67,"value":41375.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":38775,"source":{"system":"sec-edgar","filing":"0001209191-21-031376","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121031376/doc4.xml","form_type":"4"}},{"id":2744857,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option","published_at":"2021-04-19T21:17:39.000Z","date":"2021-04-15","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the \"Option Anniversary Date\") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant date."}],"balance_after":58000,"derivative":{"exercise_price":55,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-027329","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121027329/doc4.xml","form_type":"4"}},{"id":2744856,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-19T21:17:39.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":5000,"price":109.09,"value":545450.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.35 to $110.12 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":39139,"source":{"system":"sec-edgar","filing":"0001209191-21-027329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121027329/doc4.xml","form_type":"4"}},{"id":2744855,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-04-19T21:17:39.000Z","date":"2021-04-15","kind":"exercise","acquired":true,"shares":5000,"price":55,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":44139,"source":{"system":"sec-edgar","filing":"0001209191-21-027329","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121027329/doc4.xml","form_type":"4"}},{"id":2812093,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right o Buy)","published_at":"2021-03-04T01:37:53.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":11000,"derivative":{"exercise_price":142.47,"expiration_date":"2031-03-01","underlying":"Common Stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001209191-21-017538","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121017538/doc4.xml","form_type":"4"}},{"id":2812092,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:37:53.000Z","date":"2021-03-01","kind":"sale","acquired":false,"shares":4543,"price":138.18,"value":627751.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Represents shares sold to pay required tax withholdings due to the vesting of RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.17 to $138.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":39139,"source":{"system":"sec-edgar","filing":"0001209191-21-017538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121017538/doc4.xml","form_type":"4"}},{"id":2812091,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:37:53.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":4636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents 1,530 shares of common stock and 3,106 RSUs into which previously granted performance stock units were converted on March 1, 2021 upon certification of the performance metric. The RSUs will fully vest on March 1, 2022."}],"balance_after":43682,"source":{"system":"sec-edgar","filing":"0001209191-21-017538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121017538/doc4.xml","form_type":"4"}},{"id":2812090,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-03-04T01:37:53.000Z","date":"2021-03-01","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":39046,"source":{"system":"sec-edgar","filing":"0001209191-21-017538","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121017538/doc4.xml","form_type":"4"}},{"id":2884973,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-02-02T21:28:49.000Z","date":"2021-01-30","kind":"sale","acquired":false,"shares":2243,"price":140.36,"value":314827.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":33546,"source":{"system":"sec-edgar","filing":"0001209191-21-006787","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121006787/doc4.xml","form_type":"4"}},{"id":2904024,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-19T21:01:16.000Z","date":"2021-01-15","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vested with respect to 1/4th of the shares on January 30, 2019 (the first anniversary of the grant date of the option or the \"Option Anniversary Date\") and 1/48th of the shares initially subject to the option continued to vest on each month as measured from the Option Anniversary Date such that the option will fully vest on the fourth anniversary of the grant dat."}],"balance_after":63000,"derivative":{"exercise_price":55,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-003992","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121003992/doc4.xml","form_type":"4"}},{"id":2904023,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-19T21:01:16.000Z","date":"2021-01-15","kind":"sale","acquired":false,"shares":25000,"price":139.18,"value":3479500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.69 to $141.80 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":35789,"source":{"system":"sec-edgar","filing":"0001209191-21-003992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121003992/doc4.xml","form_type":"4"}},{"id":2904022,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2021-01-19T21:01:16.000Z","date":"2021-01-15","kind":"exercise","acquired":true,"shares":25000,"price":55,"value":1375000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":60789,"source":{"system":"sec-edgar","filing":"0001209191-21-003992","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919121003992/doc4.xml","form_type":"4"}},{"id":2948255,"issuer":{"id":3693,"kind":"organization","name":"RHYTHM PHARMACEUTICALS, INC.","symbol":"RYTM"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-11T21:11:27.000Z","date":"2020-12-09","kind":"grant","acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the options will vest on each one-year anniversary of the grant date, with the first one-third vesting on December 9, 2021."}],"balance_after":37000,"derivative":{"exercise_price":28.27,"expiration_date":"2030-12-08","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0001104659-20-134778","document":"tm2038260-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000110465920134778/tm2038260-3_4seq1.xml","form_type":"4"}},{"id":3004963,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-10-16T23:22:24.000Z","date":"2020-10-14","kind":"sale","acquired":false,"shares":262,"price":88,"value":23056.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":35789,"source":{"system":"sec-edgar","filing":"0001209191-20-055180","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120055180/doc4.xml","form_type":"4"}},{"id":3039309,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-09-03T21:58:35.000Z","date":"2020-09-01","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in three substantially equal annual installments on each of the first three anniversaries of the grant date, subject to continued service as a director through each such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":16.08,"expiration_date":"2030-08-31","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-049518","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919120049518/doc4.xml","form_type":"4"}},{"id":3156077,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-09T00:12:15.000Z","date":"2020-05-06","kind":"tax_withholding","acquired":false,"shares":249,"price":66.26,"value":16498.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units (\"RSUs\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":36051,"source":{"system":"sec-edgar","filing":"0001209191-20-028118","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120028118/doc4.xml","form_type":"4"}},{"id":3231313,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T00:45:23.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":21000,"derivative":{"exercise_price":56.08,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001209191-20-015735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120015735/doc4.xml","form_type":"4"}},{"id":3231312,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-04T00:45:23.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":1249,"price":56.08,"value":70043.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":36300,"source":{"system":"sec-edgar","filing":"0001209191-20-015735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120015735/doc4.xml","form_type":"4"}},{"id":3231311,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-04T00:45:23.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":5634,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents 1,859 shares of common stock and 3,775 RSUs into which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":37549,"source":{"system":"sec-edgar","filing":"0001209191-20-015735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120015735/doc4.xml","form_type":"4"}},{"id":3231310,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-03-04T00:45:23.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":7300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":31915,"source":{"system":"sec-edgar","filing":"0001209191-20-015735","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120015735/doc4.xml","form_type":"4"}},{"id":3296416,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-01-31T18:58:58.000Z","date":"2020-01-30","kind":"tax_withholding","acquired":false,"shares":1624,"price":53.23,"value":86445.52,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":24615,"source":{"system":"sec-edgar","filing":"0001209191-20-005730","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919120005730/doc4.xml","form_type":"4"}},{"id":3392758,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-10-16T23:24:16.000Z","date":"2019-10-14","kind":"grant","acquired":true,"shares":1437,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":26239,"source":{"system":"sec-edgar","filing":"0001209191-19-053321","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919119053321/doc4.xml","form_type":"4"}},{"id":3536294,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-05-07T22:55:13.000Z","date":"2019-05-06","kind":"grant","acquired":true,"shares":1438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":24802,"source":{"system":"sec-edgar","filing":"0001209191-19-028091","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919119028091/doc4.xml","form_type":"4"}},{"id":3618303,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-04T22:09:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":21500,"derivative":{"exercise_price":67.55,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001209191-19-015744","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919119015744/doc4.xml","form_type":"4"}},{"id":3618302,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-03-04T22:09:26.000Z","date":"2019-03-01","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23364,"source":{"system":"sec-edgar","filing":"0001209191-19-015744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919119015744/doc4.xml","form_type":"4"}},{"id":3653394,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2019-02-15T22:49:51.000Z","date":"2019-01-30","kind":"tax_withholding","acquired":false,"shares":1636,"price":48.85,"value":79918.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":16364,"source":{"system":"sec-edgar","filing":"0001209191-19-010740","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919119010740/doc4.xml","form_type":"4"}},{"id":4083368,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-01-31T23:39:34.000Z","date":"2018-01-30","kind":"grant","acquired":true,"shares":88000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On the first anniversary of the grant date of the option (the \"Option Anniversary Date\"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date."}],"balance_after":88000,"derivative":{"exercise_price":55,"expiration_date":"2028-01-30","underlying":"Common Stock","underlying_shares":88000},"source":{"system":"sec-edgar","filing":"0001209191-18-006301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919118006301/doc4.xml","form_type":"4"}},{"id":4083367,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17931,"kind":"person","name":"Bedrosian Camille L","position":1,"cik":"0001326969","reported_name":"Bedrosian Camille L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP and Chief Medical Officer"}}],"security":"Common Stock","published_at":"2018-01-31T23:39:34.000Z","date":"2018-01-30","kind":"grant","acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date."}],"balance_after":18000,"source":{"system":"sec-edgar","filing":"0001209191-18-006301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326969/000120919118006301/doc4.xml","form_type":"4"}}]}